11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors still improve metabolic phenotype in male 11β-HSD1 knockout mice suggesting off-target mechanisms

Endocrinology

Volumn 154, Issue 12, 2013, Pages 4580-4593

  Harno, Erika ^a   Cottrell, Elizabeth C ^b   Yu, Alice ^c   DeSchoolmeester, Joanne ^c   Gutierrez, Pablo Morentin ^c   Denn, Mark ^c   Swales, John G ^c   Goldberg, Fred W ^c   Bohlooly Y, Mohammad ^d   Andersén, Harriet ^d   Wild, Martin J ^c   Turnbull, Andrew V ^c   Leighton, Brendan ^c   White, Anne ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 2 [2,6 DIMETHYLMORPHOLIN 4 YL] N (5 HYDROXY 2 ADAMANTYL) 4 [OXOLAN 2 YL]PYRAMIDINE 5 CARBOXAMIDE; CORTICOSTERONE; GLUCOSE; MK 0916; NESTIN; OXIDOREDUCTASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; (6-(4-(2-PIPERIDIN-1-YLETHOXY)PHENYL))-3-PYRIDIN-4-YLPYRAZOLO(1,5-A)PYRIMIDINE; ANTIDIABETIC AGENT; FAT INTAKE; GLUCOSE BLOOD LEVEL; INSULIN; MESSENGER RNA; MK-0916; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIET RESTRICTION; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FAT MASS; FOOD INTAKE; GENOTYPE; GLUCOSE INTAKE; IC 50; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; LIPID DIET; MALE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WEIGHT REDUCTION; ADIPOSE TISSUE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENERGY METABOLISM; FAT INTAKE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE BLOOD LEVEL; KNOCKOUT MOUSE; LIVER; METABOLISM;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; BRAIN; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MALE; MICE; MICE, KNOCKOUT; MOLECULAR STRUCTURE; PYRAZOLES; PYRIMIDINES; RNA, MESSENGER; TRIAZOLES;

EID: 84888262119     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1613     Document Type: Article

References (45)

1. Reaven GM. Why syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab. 2005;1:9-14.
2. Pavlatou MG, Vickers KC, Varma S, et al. Circulating cortisol-associated signature of glucocorticoid-related gene expression in subcutaneous fat of obese subjects. Obesity. 2013;21:960-967.
3. Walker BR. Cortisol-cause and cure for metabolic syndrome? Diabetic Med. 2006;23:1281-1288.
4. Rask E, Olsson T, Söderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab. 2001;86:1418-1421.
5. Valsamakis G, Anwar A, Tomlinson JW, et al. 11β-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2004;89:4755-4761.
6. Westerbacka J, Cornér A, Kannisto K, et al. Acute in vivo effects of insulin on gene expression in adipose tissue in insulin-resistant and insulin-sensitive subjects. Diabetologia. 2006;49:132-140.
7. Sjöstrand M, Jansson PA, Palming J, et al. Repeated measurements of 11β-HSD-1 activity in subcutaneous adipose tissue from lean, abdominally obese, and type 2 diabetes subjects-no change following a mixed meal. Horm Metab Res. 2010;42:798-802.
8. Morton NM. Obesity and corticosteroids: 11β-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol. 2010;316:154-164.
9. Gathercole LL, Stewart PM. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J Steroid Biochem Mol Biol. 2010;122:21-27.
10. Densmore VS, Morton NM, Mullins JJ, Seckl JR. 11β-Hydroxysteroid dehydrogenase type 1 induction in the arcuate nucleus by high-fat feeding: a novel constraint to hyperphagia? Endocrinology. 2006;147:4486-4495.
11. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorti-coid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA. 1997;94:14924-14929.
12. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166-2170.
13. Morgan SA, Sherlock M, Gathercole LL, et al. 11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes. 2009;58:2506-2515.
14. Véniant MM, Hale C, Komorowski R, Chen MM, et al. Time of the day for 11β-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice. Diabetes Obes Metab. 2009;11:109-117.
15. Wan ZK, Chenail E, Xiang J, et al. Efficacious 11β-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model. J Med Chem. 2009;52:5449-5461.
16. Wang SJ, Birtles S, de Schoolmeester J, et al. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia. 2006;49:1333-1337.
17. Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med. 2005;202:517-527.
18. Rosenstock J, Banarer S, Fonseca VA, et al. The 11-β-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care . 2010;33:1516-1522.
19. Feig PU, Shah S, Hermanowski-Vosatka A, et al. Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab. 2011;13:498-504.
20. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 1999;21:70-71.
21. Goldberg FW, Leach AG, Scott JS, et al. Free-Wilson and structural approaches to co-optimizing human and rodent isoform potency for 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors. J Med Chem. 2012;55:10652-10661.
22. Scott JS, Gill AL, Godfrey L, et al. Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors. Bioorg Med Chem Lett. 2012;22:6756-6761.
23. Bauman DR, Whitehead A, Contino LC, et al. Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension. Bioorg Med Chem Lett. 2013;23:3650-3653.
24. Wright DH, Stone JA, Crumley TM, et al. Pharmacokinetic/pharmacodynamic studies of the 11β-HSD1 inhibitor MK-0916 in healthy subjects [published online ahead of print April 18, 2013]. Br J Clin Pharmacol. doi:10.1111/bcp. 12131.
25. Buttar D, Colclough N, Gerhardt S, et al. A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions. Bioorg Med Chem. 2010;18:7486-7496.
26. Zakrzewska KE, Cusin I, Stricker-Krongrad A, et al. Induction of obesity and hyperleptinemia by central glucocorticoid infusion in the rat. Diabetes. 1999;48:365-370.
27. Yi CX,Foppen E, Abplanalp W, et al. Glucocorticoid signaling in the arcuate nucleus modulates hepatic insulin sensitivity. Diabetes. 2012;61:339-345.
28. Cusin I, Rouru J, Rohner-Jeanrenaud F. Intracerebroventricular glucocorticoid infusion in normal rats: induction of parasympatheticmediated obesity and insulin resistance. Obes Res. 2001;9:401-406.
29. Harno E, Cottrell EC, White A. Metabolic pitfalls of CNS cre-based technology. Cell Metab. 2013;18:21-28.
30. Briancon N, McNay DE, Maratos-Flier E, Flier JS. Combined neural inactivation of suppressor of cytokine signaling-3 and protein-tyrosine phosphatase-1B reveals additive, synergistic, and factor-specific roles in the regulation of body energy balance. Diabetes. 2010;59:3074-3084.
31. Shah S, Hermanowski-Vosatka A, Gibson K, et al. Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. J Am Soc Hypertens. 2011;5:166-176.
32. Michailidou Z, Turban S, Miller E, et al. Increased angiogenesis protects against adipose hypoxia and fibrosis in metabolic diseaseresistant 11β-hydroxysteroid dehydrogenase type 1 (HSD1)-deficient mice. J Biol Chem. 2012;287:4188-4197.
33. Nixon M, Wake DJ, Livingstone DE, et al. Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization. Diabetes . 2012;61:790-796.
34. Hawkins M, Hunter D, Kishore P, et al. INCB13739, a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), improved insulin sensitivity and lowers plasma cholesterol over 28 days in patients with type 2 diabetes mellitus. Diabetes. 2008; 57(suppl 1):A99-A100.
35. Hollis G, Huber R. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13:1-6.
36. Morton NM, Ramage L, Seckl JR. Down-regulation of adipose 11β-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease. Endocrinology. 2004;145:2707-2712.
37. Yau JL, Seckl JR. 11β-Hydroxysteroid dehydrogenase type I in the brain; thickening the glucocorticoid soup. Mol Psychiatry. 2001;6:611-614.
38. Bisschop PH, Dekker MJ, Osterthun W, et al. Expression of 11β-hydroxysteroid dehydrogenase type 1 in the human hypothalamus. J Neuroendocrinol. 2013;25:425-432.
39. Savontaus E, Conwell IM, Wardlaw SL. Effects of adrenalectomy on AGRP, POMC, NPY and CART gene expression in the basal hypothalamus of fed and fasted rats. Brain Res. 2002;958:130-138.
40. Beaulieu S, Gagné B, Barden N. Glucocorticoid regulation of proopiomelanocortin messenger ribonucleic acid content of rat hypothalamus. Mol Endocrinol. 1988;2:727-731.
41. Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissuemediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes. 2004;53:931-938.
42. Wamil M, Battle JH, Turban S, et al. Novel fat depot-specific mechanisms underlie resistance to visceral obesity and inflammation in 11β- hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes. 2011;60:1158-1167.
43. Harno E, White A. Will treating diabetes with 11β-HSD1 inhibitors affect the HPA axis? Trends Endocrinol Metab. 2010;21:619-627.
44. Iqbal J, Macdonald LJ, Low L, et al. Contribution of endogenous glucocorticoids and their intravascular metabolism by 11β-HSDs to postangioplasty neointimal proliferation in mice. Endocrinology. 012;153:5896-5905.
45. Garcia RA, Search DJ, Lupisella JA, et al. 11β-hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE(-)/(-) mice. PloS One. 2013;8:e53192.